Medical network on June 14th - July 1, the method of traditional Chinese medicine is about to fall to the ground, the proprietary Chinese medicine industry caught the attention of the industry, especially anti-tumor proprietary Chinese medicine, part of the enterprise as a key product layout. Experts say that in the context of the combination of Chinese and western cancer treatment, there is more room for the drug to be taken out of the tumor. However, due to the lack of effective clinical data in most anti-tumor drugs, it is still difficult to break through the chemical and biological agents. 

 

▍ markets: companies launched antitumor proprietary Chinese medicine 

 

Anti-cancer drugs have long been a gold mine for many drug companies. In terms of the domestic market, according to McKinsey, released in 2015, the China hospital drug use observation, according to a report in domestic hospital channel antitumor drugs market since 2012 to 2014, compound annual growth rate of 17%, in 2014 sales of about 46 billion yuan RMB, the strong growth will continue in the future. 

 

According to the classification of CMH, the current domestic market of antitumor medicine mainly includes metabolic resistance, proprietary Chinese medicine, hormonal, sheet resistance and protein kinase inhibitors, etc., among them, the anti-tumor proprietary Chinese medicine is "outstanding". 

 

In recent years, many domestic drug firms focus on layout antitumor drugs, such as ridge pharmaceutical ideas away capsule, step length pharmaceutical product ideas mixture, tasly pharmaceutical, red sun pharmaceutical anti-cancer pill (products) after acquisition of hainan Long Shengtang and li li, zhejiang pharmaceutical injection coix seed extract (Chinese medicine), etc., are all make drug firms focus on variety, occupy a considerable share in the market. 

 

This year, in the positive context of the coming implementation of the TCM law, some pharmaceutical companies have launched new anti-tumor drugs and want a share of the market. 

 

Guangzhou baiyun mountain, for example, a pharmaceutical industry (hereinafter referred to as a pharmaceutical) announced on May 12, the treatment of breast cancer, liver cancer and other malignant tumors of proprietary Chinese medicine "west yellow pill" officially put on the market. Although the national food administration of drug safety, according to west yellow pill now has 64 production approval, but in the pharmaceutical industry to "Chinese medicine cancer the first medicine" future expectations high, according to the relevant person in charge of the company Marketing Department, after the product is expected to reach sales of 100 million yuan or so. 

 

▍ analysis: "combination of Chinese and western of proprietary Chinese medicine" or" 

 

According to the national people club department released in February 21, according to the basic medical insurance directory "2017" target the use of proprietary Chinese medicine for a total of 44 species (41) a three, b, including antitumor medicine to 22 species, auxiliary treatment of 22 kinds of; There is still a gap between the 119 categories of western medicine. 

 

In tumor treatment status, drugs, radiation therapy and surgery are the three treatments, natural plant extracts, chemicals and resistance to targeted drugs is applied more widely, such as antitumor drugs, no matter in what kind of treatment, proprietary Chinese medicine are in a position of "auxiliary treatment". 

 

In the eyes of experts, there is a lot of room for the future of anti-tumor medicine in the context of the combination of Chinese and western medicine. Chinese academy of engineering zhao-you tang, in an interview with the information times reporter said that the tumor treatment at the same time of learning the western must be combined with national conditions, cancer prevention and control should be eliminated and the modification and the method of combination of Chinese and western. 

 

"Although in technology, equipment and methods, drugs, radiation and surgery has many improvements, but unfortunately, these treatments are used to eliminate the strategy, in kill cancer at the same time, also have side effects. The transformation of Chinese style is a transformation of the body, main is to improve the body resistance, in order to more effectively play its power against the residual carcinoma; second, on the residual carcinoma, make it right." 

 

Zhao-you tang pointed out that the western medicine pays attention to micro and local, Chinese macroeconomic and overall, if the combination of both will "promising" in the future, especially in proprietary Chinese medicine research. There are a lot of research confirmed that Chinese medicine treatment for "anti-inflammatory" does have some effect, for example, in Japan studies have confirmed that small bupleurum decoction can reduce the inflammatory response. 

 

▍ basic-level hospitals or into anti-tumor traditional new channels 

 

It is understood that the main circulation channel for oncology drugs is the hospital. The personage inside course of study says, now in the hospital channel, antitumor proprietary Chinese medicine more compete in traditional channels, this means that the antitumor proprietary Chinese medicine can be "quantity", to see whether the drug to open quantity big, medical care, hospitals have also open up new sales channels. 

 

Some products with its exclusive sex into medical insurance directory, such as ridge pharmaceutical anti-tumor medicine main varieties - ideas are negative capsule, its current of 2017 b antineoplastic drugs in basic medical insurance directory - the company 2016 annual report showed that last year, the drug has entered 1 provinces basic medicine catalogue and 1 provincial new farming drug directory, and are more widely "in clinical application. 

 

It is understood that a pharmaceutical west yellow pill, takes a different approach, mainly cooperate with big pharmacy, after the listing by DTP pharmacy (i.e., consumers with prescription outside buy medicine hospital) to promote products. After the traditional Chinese medicine law, doctors in the clinic will be carried out in the form of records, the future "blossoming" clinic of traditional Chinese medicine may be antitumor proprietary Chinese medicine "quantity" is one of the important channels. 

 

A few days ago, a pharmaceutical marketing chief, told reporters that in the act of traditional Chinese medicine and hierarchical diagnosis and treatment, etc. Under the New Deal is good, anti-tumor proprietary Chinese medicine sales will grow. One is that county hospitals must set up oncology specialties, and a large number of late-stage cancers that are not suitable for surgical treatment remain at the grassroots level for conservative treatment. Second, with the development of the graded treatment, a certain amount of postoperative cancer patients need to be transferred to the primary care system. Three is part of the provinces and cities has clear poverty "nine basic point treatment of a serious illness," which "esophageal cancer, gastric cancer, rectal cancer, colon cancer" is must treatment program. "In the future, the grassroots will likely be a new channel for anti-tumor growth." "Said the person in charge. 

 

▍ lack of clinical data, "adjuvant" status is difficult to change 

 

Recently, the Beijing minister medical consultation center director Shi Lichen said when accepting a reporter to interview, no matter future how many new drug sales channels, antitumor proprietary Chinese medicine after "amount" is still difficult to reverse "adjuvant" awkward position. 

 

"In circulation in the hospital medicine, natural medicine, or single anti tumor drug products, there are clear clinical data and adapt to the indications, the doctor prescribe are relatively clear understanding of the drug. But proprietary Chinese medicine, clinical data and most of the products is not exact therapeutic effect, drug curative effect and risk brought by the unknown, so the doctor in the treatment, proprietary Chinese medicine against tumor is can open is not open, even if the amount is far less than the current tumor treatment medicine." Shi Lichen said.